长链非编码RNA ZEB1-AS1/miR-625-5p轴在脓毒症相关急性肾损伤中的诊断和预后潜力及机制研究
本研究纳入脓毒症患者(分为非急性肾损伤组和脓毒症相关急性肾损伤组)及健康对照,检测血清ZEB1-AS1、miR-625-5p和RUNX1水平。脓毒症相关急性肾损伤患者ZEB1-AS1显著升高、miR-625-5p显著降低;ZEB1-AS1诊断急性肾损伤的AUC为0.824,miR-625-5p为0.811,二者联合AUC为0.917。高ZEB1-AS1或低miR-625-5p水平预示脓毒症相关急性肾损伤患者生存不良。机制上ZEB1-AS1直接结合并抑制miR-625-5p,RUNX1为miR-625-5p直接靶点;脂多糖刺激的HK-2细胞中ZEB1-AS1过表达加重凋亡和炎症,敲低则逆转。
要点
- 脓毒症相关急性肾损伤患者血清ZEB1-AS1较非急性肾损伤患者和健康对照显著升高,miR-625-5p显著降低。
- ZEB1-AS1诊断脓毒症患者急性肾损伤的AUC为0.824,miR-625-5p为0.811,二者联合AUC为0.917。
- 高ZEB1-AS1或低miR-625-5p水平预示脓毒症相关急性肾损伤患者生存不良。
- 机制上ZEB1-AS1直接结合并抑制miR-625-5p,RUNX1为miR-625-5p直接靶点,与ZEB1-AS1正相关、与miR-625-5p负相关。
- 脂多糖刺激的HK-2细胞中,ZEB1-AS1过表达加重凋亡和炎症,si-ZEB1-AS1敲低可逆转;抑制miR-625-5p可抵消敲低ZEB1-AS1的保护作用。
适用人群与场景
- 脓毒症患者,分为非急性肾损伤组和脓毒症相关急性肾损伤组,另设健康对照。
研究设计与关键结果
- 研究纳入脓毒症患者(非急性肾损伤组和脓毒症相关急性肾损伤组)及健康对照,采用实时定量聚合酶链反应检测血清ZEB1-AS1、miR-625-5p和RUNX1水平。
- 脓毒症相关急性肾损伤患者ZEB1-AS1较非急性肾损伤患者和健康对照显著升高,miR-625-5p显著降低。
- ZEB1-AS1诊断脓毒症患者急性肾损伤的AUC为0.824,miR-625-5p的AUC为0.811,二者联合AUC为0.917。
- 高ZEB1-AS1或低miR-625-5p水平预示脓毒症相关急性肾损伤患者生存不良。
- 双荧光素酶报告基因实验、RNA免疫沉淀和相关性分析验证ZEB1-AS1直接结合并抑制miR-625-5p,RUNX1为miR-625-5p直接靶点,与ZEB1-AS1正相关、与miR-625-5p负相关。
- 脂多糖刺激的HK-2细胞中,ZEB1-AS1过表达加重凋亡和炎症,si-ZEB1-AS1敲低可逆转;抑制miR-625-5p可抵消敲低ZEB1-AS1的保护作用,沉默RUNX1可恢复细胞活力。
证据类型、等级与局限
- 证据类型:临床队列结合体外细胞实验(病例对照及机制研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ZEB1-AS1和miR-625-5p有望作为脓毒症相关急性肾损伤的诊断和预后生物标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-associated acute kidney injury (S-AKI) is a life-threatening complication of sepsis, characterized by severe renal dysfunction and uncontrolled inflammation. Long noncoding RNAs have emerged as critical regulators in S-AKI pathogenesis, yet the role of long noncoding RNA ZEB1-AS1 remains unclear.
METHODS: This study enrolled sepsis patients categorized into non-AKI and S-AKI groups, with healthy controls. Serum ZEB1-AS1, miR-625-5p, and RUNX1 levels were quantified by real-time quantitative polymerase chain reaction. Logistic regression and receiver operating characteristic analysis evaluated the biomarker diagnostic value. Molecular interactions between ZEB1-AS1, miR-625-5p, and RUNX1 were validated using dual-luciferase reporter assays, RNA immunoprecipitation, and correlation analysis. In vitro experiments used lipopolysaccharide-stimulated HK-2 cells with siRNA transfection to investigate functional roles.
RESULTS: S-AKI patients showed significantly elevated ZEB1-AS1 and reduced miR-625-5p expression compared with non-AKI patients and healthy controls. ZEB1-AS1 achieved an area under the curve (AUC) of 0.824 for diagnosing AKI in sepsis, while miR-625-5p had an AUC of 0.811; their combination improved accuracy (AUC = 0.917). High ZEB1-AS1 or low miR-625-5p levels predicted poor survival in S-AKI patients. Mechanistically, ZEB1-AS1 directly bound miR-625-5p, suppressing its activity. RUNX1, a direct target of miR-625-5p, showed a positive correlation with ZEB1-AS1 and a negative correlation with miR-625-5p. In lipopolysaccharide-treated HK-2 cells, ZEB1-AS1 overexpression exacerbated apoptosis and inflammation, which was reversed by si-ZEB1-AS1-mediated knockdown. Inhibiting miR-625-5p counteracted the protective effects of ZEB1-AS1 knockdown, while RUNX1 silencing restored cell viability.
CONCLUSIONS: ZEB1-AS1 and miR-625-5p show promise as diagnostic and prognostic biomarkers for S-AKI. The ZEB1-AS1/miR-625-5p/RUNX1 axis drives tubular injury and inflammation in S-AKI.
参考来源
- Yu X, Chen D, Liu F, et al. The LNCRNA ZEB1-AS1/MIR-625-5P Axis: Diagnostic and Prognostic Potential and Mechanistic Insights in Sepsis-Associated Acute Kidney Injury. Shock. 2026. PMID: 41735176. doi:10.1097/SHK.0000000000002808
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。